In line with these findings, we showed that STAT3-deficient neutrophils increase their expression of MHCII, CD80/86, and ICAM-1 and operate by licensing antitumoral cytotoxic CD8+ T cell responses rather than by direct killing of tumor cells. This evidence concerns the gene CD8A and neoplasm.